News - Celgene

Filter

Current filters:

Celgene

Popular Filters

1 to 25 of 102 results

Celgene’s Otezla misses endpoint in Ph III ankylosing spondylitis study

Celgene’s Otezla misses endpoint in Ph III ankylosing spondylitis study

09-07-2014

Shares of US biotech firm Celgene fell 3.5% in premarket trade, but were up 1.2% $86.75 by mid-morning…

Anti-Arthritics/RheumaticsBiotechnologyCelgeneOtezlaResearchUSA

Intas reinforces cancer range with the first time launch of Azadine in India

25-06-2014

Indian drugmaker Intas Pharmaceuticals says it has reinforced its oncology product range by successfully…

AzadineCelgeneGenericsIndiaIntas PharmaceuticalsMarkets & MarketingOncologyVidaza

FTC amicus brief: Improper use of restricted drug distribution programs may impede generic competition

FTC amicus brief: Improper use of restricted drug distribution programs may impede generic competition

20-06-2014

The US Federal Trade Commission has filed an amicus brief in the New Jersey US District Court explaining…

CelgeneGenericsLegalMylanPharmaceuticalRegulationUSA

Celgene exercises option for Agios Pharma’s AG-221

Celgene exercises option for Agios Pharma’s AG-221

17-06-2014

Metabolism specialist Agios Pharmaceuticals says that its partner, biotech major Celgene Corp, has exercised…

AG-221Agios PharmaceuticalsBiotechnologyCelgeneLicensingOncologyRegulationResearchUSA

EHA 2014: Celgene announces results on Pomalyst, Vidaza and beta-thalassemia collaboration

EHA 2014: Celgene announces results on Pomalyst, Vidaza and beta-thalassemia collaboration

16-06-2014

Among companies presenting results from across the board at the European Hematology Association annual…

Beta-thalassemiaCelgeneEuropeHematologyPharmaceuticalpomalidomideResearchVidaza

ASCO 2014: Takeda, Roche and Celgene present results

ASCO 2014: Takeda, Roche and Celgene present results

02-06-2014

A host of results have been presented by global pharma majors at the 2014 Annual Meeting of the American…

AbraxaneCelgeneOncologyPharmaceuticalResearchRocheTakeda PharmaceuticalsUSAVelcade

Celgene announce organizational changes to leadership team

Celgene announce organizational changes to leadership team

23-05-2014

US biotech company Celgene Corp (Nasdaq: CELG) has announced organizational changes to its leadership…

BiotechnologyBoardroomCelgeneUSA

NICE draft guidance negative on Celgene’s Revlimid

20-05-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) has today issued…

BiotechnologyCelgeneOncologyPricingRegulationRevlimidUK

AADi in-licenses Celgene’s ABI-009

20-05-2014

US clinical-stage biopharma company AADi says it has in-licensed ABI-009 from biotech firm Celgene. Financial…

AADiABI-009BiotechnologyCardio-vascularCelgeneOncologyRespiratory and Pulmonary

Celgene gains rights to Nogra product in potential $1 billion-plus deal

Celgene gains rights to Nogra product in potential $1 billion-plus deal

24-04-2014

US biotech firm Celgene has entered a global license agreement with privately-held Irish company Nogra…

Anti-Arthritics/RheumaticsBiotechnologyCelgeneGED-0301LicensingNogra Pharma

Celgene beats expectations, despite profit downturn

24-04-2014

US biotech firm Celgene saw its shares fall 3.3% to $140.05 in mid-morning trading after it posted first-quarter…

BiotechnologyCelgeneFinancial

Pharmaceutical companies to benefit from new blood cancer drugs

04-04-2014

Blood cancer drugs represent a growth opportunity for the pharmaceutical industry over the next few years,…

AmgenCelgeneGilead SciencesJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRoche

Second collaboration between FORMA Therapeutics and Celgene

02-04-2014

Privately-held drug discovery firm FORMA Therapeutics has entered a second strategic collaboration and…

BiotechnologyCelgeneFORMA TherapeuticsLicensingMergers & AcquisitionsResearch

Pancreatic cancer drug market in 6 major markets to see CAGR of 25% to 2017

Pancreatic cancer drug market in 6 major markets to see CAGR of 25% to 2017

01-04-2014

The global pancreatic cancer treatment market value in the six major countries (6MM: the USA, France,…

AbraxaneBiotechnologyCelgeneEuropeMarkets & MarketingOncologyUSA

Positive Ph III results with oral Otezla in skin, nail and scalp of patients with plaque psoriasis

24-03-2014

US biotech firm Celgene has released positive new research findings on Otezla (apremilast), an oral,…

apremilastBiotechnologyCelgeneDermatologicalsOtezlaResearch

Celgene’s Otezla is first oral therapy OKed by FDA for adults with active psoriatic arthritis

23-03-2014

The US Food and Drug Administration on Friday approved US biotech firm Celgene’s Otezla (apremilast),…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneNorth AmericaOtezlaRegulationUSA

New survey confirms psoriasis and psoriatic arthritis patients frequently undertreated or not treated at all

21-03-2014

A unique and extensive survey provides the first-of-its-kind multinational look into the impact psoriasis…

Anti-Arthritics/RheumaticsCelgeneDermatologicalsHealthcarePharmaceutical

Celgene UK and Ireland appoint Rob Moore as Inflammation and Immunology Business Unit Director

Celgene UK and Ireland appoint Rob Moore as Inflammation and Immunology Business Unit Director

19-03-2014

Celgene UK and Ireland have announced the appointment of Rob Moore as the new Inflammation and Immunology…

BiotechnologyBoardroomCelgeneNorthern EuropeUK

NICE says better information needed on Celgene’s MM drug

NICE says better information needed on Celgene’s MM drug

14-03-2014

The UK drugs watchdog, the National Institute for Health and care Excellence (NICE) says that, based…

BiotechnologyCelgeneNorthern EuropeOncologyPricingRegulationRevlimidUK

Abide Therapeutics in deal with Celgene on immune disorders research

03-03-2014

Privately-held Abide Therapeutics has entered into a strategic collaboration with US biotech firm Celgene…

AB101131Abide TherapeuticsBiotechnologyCelgeneImmunologicalsInflammatory diseasesLicensingMergers & Acquisitions

Genentech regains its dominance in image among oncologists

Genentech regains its dominance in image among oncologists

20-02-2014

Genentech, the biotechnology subsidiary of Swiss drug major Roche, has made notable gains as the top…

AmgenBiotechnologyCelgeneGenentechHematologyMarkets & MarketingNovartisOncologyResearch

Health Canada approves Celgene’s Pomalyst for multiple myeloma

Health Canada approves Celgene’s Pomalyst for multiple myeloma

12-02-2014

Regulatory agency Health Canada has approved US biotech firm Celgene’s drug Pomalyst (pomalidomide…

BiotechnologyCanadaCelgeneNorth AmericaOncologyPomalystRegulation

Whistleblower law suit against Celgene unsealed

Whistleblower law suit against Celgene unsealed

07-02-2014

A US federal court yesterday unsealed a whistleblower/false claims law suit brought against US biotech…

BiotechnologyCelgeneLegalMarkets & MarketingNorth AmericaOncologyRevlimidThalomidUSA

1 to 25 of 102 results

Back to top